# Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer

> **NCT00962312** · PHASE2 · COMPLETED · sponsor: **Cancer Trials Ireland** · enrollment: 9 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** capecitabine
- **DRUG:** lapatinib ditosylate

## Key facts

- **NCT ID:** NCT00962312
- **Lead sponsor:** Cancer Trials Ireland
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2010-12
- **Final completion:** —
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2014-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00962312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00962312, "Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00962312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*